Arsenic and Chronic Kidney Disease: A Systematic Review

Current environmental health reports

Volumn 1, Issue 3, 2014, Pages 192-207

  Zheng, Laura ^a   Kuo, Chin Chi ^a   Fadrowski, Jeffrey ^b   Agnew, Jackie ^a   Weaver, Virginia M ^a,c   Navas Acien, Ana ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Arsenic; Kidney; Kidney disease; Proteinuria; Systematic review

Indexed keywords

EID: 84914703524     PISSN: None     EISSN: 21965412     Source Type: Journal    
DOI: 10.1007/s40572-014-0024-x     Document Type: Review

References (79)

1. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett. 2002;133:1–16.
2. Nordstrom DK. Public health. Worldwide occurrences of arsenic in ground water. Science. 2002;296:2143–5.
3. Smith AH, Steinmaus CM. Arsenic in drinking water. BMJ. 2011;342:d2248.
4. Naujokas MF, Anderson B, Ahsan H, et al. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect. 2013;121:295–302.
5. Smedley PL, Kinniburgh DG. A review of the source, behaviour and distribution of arsenic in natural waters. Appl Geochem. 2002;17:517–68.
6. Arsenic: Environmental Chemistry, Health Threats, and Waste Treatment. West Sussex, UK: John Wiley & Sons, Ltd; 2009.
7. Navas-Acien A, Sharrett AR, Silbergeld EK, et al. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol. 2005;162:1037–49.
8. International Agency for Research on Cancer. Some drinking-water disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum. 2004; 84:1–477.
9. Moon KA, Guallar E, Umans JG, et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort Study. Ann Intern Med Under. 2013;159:649–59.
10. Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diabetes Rep. 2013;13:831–49.
11. Maull EA, Ahsan H, Edwards J, et al. Evaluation of the Association between Arsenic and Diabetes: A National Toxicology Program Workshop Review. Environ Health Perspect. 2012;120:1658–70.
12. Sohel N, Vahter M, Ali M, et al. Spatial patterns of fetal loss and infant death in an arsenic-affected area in Bangladesh. Int J Health Geogr. 2010;9:53.
13. Chen Y, Parvez F, Liu M, et al. Association between arsenic exposure from drinking water and proteinuria: results from the Health Effects of Arsenic Longitudinal Study. Int J Epidemiol. 2011;828:35. This large prospective cohort study from a high arsenic area of Bangladesh looked at urine arsenic and proteinuria features both as a cross-sectional as well as a longitudinal component. This study found a positive association between urine arsenic and baseline proteinuria, as well as change in urine arsenic and incident proteinuria. It did not find an association between baseline urine arsenic and incident proteinuria.
14. Hsueh YM, Chung CJ, Shiue HS, et al. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am J Kidney Dis. 2009;54:859–70.
15. Zheng LY, Umans JG, Tellez-Plaza M, et al. Urine arsenic and prevalent albuminuria: evidence from a population-based study. Am J Kidney Dis. 2013;61:385–94. This population-based study of American Indians in low-moderate arsenic areas looked at the association between baseline urine arsenic and albuminuria. It found a positive dose-response association between urine arsenic and albuminuria, even after adjustment for potential confounders.
16. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.
17. System USRD. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In: Health NIo, ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
18. Astor BC, Levey AS, Stevens LA, Van LF, Selvin E, Coresh J. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol. 2009;20:2214–22.
19. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.
20. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–9.
21. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55.
22. O'Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney disease: one size for all ages? J Am Soc Nephrol. 2006;17:846–53.
23. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–59.
24. Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol. 2007;2:1207–14.
25. K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
26. Jung K, Pergande M, Graubaum HJ, Fels LM, Endl U, Stolte H. Urinary proteins and enzymes as early indicators of renal dysfunction in chronic exposure to cadmium. Clin Chem. 1993;39:757–65.
27. Robles-Osorio M, Perez-Maldonado IN, Martindel Campo D, et al. Urinary arsenic levels and risk of renal injury in a cross-sectional study in open population. Rev Investig Clin; Organo Hosp Enferm Nutr. 2012;64:609–14.
28. Clinical Nephrotoxins. Renal Injury from Drugs and Chemicals. 2nd ed. Dordrecht: Kluwer Academic Publishers; 2003.
29. Li Z, Piao F, Liu S, et al. Preventive effects of taurine and vitamin C on renal DNA damage of mice exposed to arsenic. J Occup Health. 2009;51:169–72.
30. Nordberg G, Jin T, Wu X, et al. Kidney dysfunction and cadmium exposure–factors influencing dose-response relationships. J Trace Elem Med Biol. 2012;26:197–200.
31. Sears ME. Chelation: harnessing and enhancing heavy metal detoxification—a review. Sci World J. 2013;2013:219840.
32. Feng H, Gao Y, Zhao L, et al. Biomarkers of renal toxicity caused by exposure to arsenic in drinking water. Environ Toxicol Pharmacol. 2013;35:495–501.
33. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA. 1988;260:652–6.
34. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect. 2012;120:494–500.
35. Moon K, Guallar E, Navas-Acien A. Arsenic exposure and cardiovascular disease:an updated systematic review. Curr Atheroscler Rep. 2012;14:542–55.
36. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.
37. Systematic Reviews in Health Care: Meta-Analysis in Context. Ed: Egger, Matthias; Smith, George Davey; Altman, Douglas G. BMJ Publishing Group; 2001.
38. Chen JW, Chen HY, Li WF, et al. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. Chemosphere. 2011;84:17–24.
39. Chen Y, Parvez F, Liu M, et al. Association between arsenic exposure from drinking water and proteinuria: results from the Health Effects of Arsenic Longitudinal Study. Int J Epidemiol. 2011;40:828–35.
40. Chiou JM, Wang SL, Chen CJ, Deng CR, Lin W, Tai TY. Arsenic ingestion and increased microvascular disease risk: observations from the south-western arseniasis-endemic area in Taiwan. Int J Epidemiol. 2005;34:936–43.
41. Hsueh YM, Chung CJ, Shiue HS, et al. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am J Kidney Dis. 2009;54:859–70.
42. Rothman K. Stratified analysis Modern Epidemiology. Boston: Little, Brown; 1986.
43. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
44. Halatek T, Sinczuk-Walczak H, Rabieh S, Wasowicz W. Association between occupational exposure to arsenic and neurological, respiratory and renal effects. Toxicol Appl Pharmacol. 2009;239:193–9.
45. Hong F, Jin TY, Lu GD, Yin ZY. Renal dysfunction in workers exposed to arsenic and cadmium]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi. Chin J Ind Hyg Occup Dis. 2003;21:432–6.
46. Hawkesworth S, Wagatsuma Y, Kippler M, et al. Early exposure to toxic metals has a limited effect on blood pressure or kidney function in later childhood, rural Bangladesh. Int J Epidemiol. 2013;42:176–85.
47. Hong F, Jin T, Zhang A. Risk assessment on renal dysfunction caused by co-exposure to arsenic and cadmium using benchmark dose calculation in a Chinese population. Biometals. 2004;17:573–80.
48. Nordberg GF, Jin T, Hong F, Zhang A, Buchet JP, Bernard A. Biomarkers of cadmium and arsenic interactions. Toxicol Appl Pharmacol. 2005;206:191–7.
49. Wang JP, Wang SL, Lin Q, Zhang L, Huang D, Ng JC. Association of arsenic and kidney dysfunction in people with diabetes and validation of its effects in rats. Environ Int. 2009;35:507–11.
50. Tsai SM, Wang TN, Ko YC. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health. 1999;54:186–93.
51. Chiu HF, Yang CY. Decreasing trend in renal disease mortality after cessation from arsenic exposure in a previous arseniasis-endemic area in southwestern Taiwan. JJ Toxicol Environ Health Part A. 2005;68:319–27.
52. Smith AH, Marshall G, Liaw J, Yuan Y, Ferreccio C, Steinmaus C. Mortality in young adults following in utero and childhood exposure to arsenic in drinking water. Environ Health Perspect. 2012;120:1527–31.
53. Jayatilake N, Mendis S, Maheepala P, Mehta FR, Team CKNRP. Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country. BMC Nephrology. 2013;14:180.
54. Eom SY, Lee YC, Yim DH, et al. Effects of low-level arsenic exposure on urinary N-acetyl-beta-D-glucosaminidase activity. Hum Exp Toxicol. 2011;30:1885–91.
55. Huang M, Choi SJ, Kim DW, et al. Risk assessment of low-level cadmium and arsenic on the kidney. J Toxicol Environ Health, Part A. 2009;72:1493–8.
56. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect. 1999;107:359–65.
57. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health. 2007;6:4.
58. Kong AP, Xiao K, Choi KC, et al. Associations between microRNA (miR-21, 126, 155 and 221), albuminuria and heavy metals in Hong Kong Chinese adolescents. Clin Chim Acta. 2012;413:1053–7.
59. Buchet JP, Heilier JF, Bernard A, et al. Urinary protein excretion in humans exposed to arsenic and cadmium. Int Arch Occup Environ Health. 2003;76:111–20.
60. Palaneeswari MS, Rajan PM, Silambanan S. Jothimalar. Blood Arsenic and Cadmium Concentrations in End-Stage Renal Disease Patients who were on Maintenance Haemodialysis. J Clin Diagn Res. 2013;7:809–13.
61. Karmaus W, Dimitrov P, Simeonov V, Tsolova S, Bonev A, Georgieva R. Metals and kidney markers in adult offspring of endemic nephropathy patients and controls: a two-year follow-up study. Environ Health. 2008;7:11.
62. Mayer DR, Kosmus W, Pogglitsch H, Mayer D, Beyer W. Essential trace elements in humans. Serum arsenic concentrations in hemodialysis patients in comparison to healthy controls. Biol Trace Elem Res. 1993;37:27–38.
63. Brandt JR, Jacobs A, Raissy HH, et al. Orthostatic proteinuria and the spectrum of diurnal variability of urinary protein excretion in healthy children. Pediatr Nephrol. 2010;25:1131–7.
64. Fowler BA, Chou SJ, Jones RL, Chen CJ. Arsenic. In: Nordberg GF, Fowler BA, Nordberg M, Freiberg LT, editors. Handbook on the Toxicology of Metals. Amsterdam: Elsevier; 2007. p. 367–443.
65. Liu J, Liu Y, Habeebu SM, Waalkes MP, Klaassen CD. Chronic combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice. Toxicology. 2000;147:157–66.
66. Li Z, Piao F, Liu S, Wang Y, Qu S. Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of mice. Exp Toxicol Pathol: Off J Ges Toxikologische Pathol. 2010;62:543–7.
67. Tsukamoto H, Parker HR, Gribble DH, Mariassy A, Peoples SA. Nephrotoxicity of sodium arsenate in dogs. Am J Vet Res. 1983;44:2324–30.
68. Escudero-Lourdes C, Medeiros MK, Cardenas-Gonzalez MC, Wnek SM, Gandolfi JA. Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol. 2010;244:162–73.
69. Ned RM, Yesupriya A, Imperatore G, et al. Inflammation gene variants and susceptibility to albuminuria in the U.S. population: analysis in the Third National Health and Nutrition Examination Survey (NHANES III), 1991-1994. BMC Med Genet. 2010;11:155.
70. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 1996;21:783–90.
71. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med. 1999;27:1405–12.
72. Shai I, Pischon T, Hu FB, Ascherio A, Rifai N, Rimm EB. Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease. Obe. Obesity(SilverSpring). 2006;14:2099–106.
73. Wijnstok NJ, Twisk JW, Young IS, et al. Inflammation markers are associated with cardiovascular diseases risk in adolescents: the Young Hearts project 2000. J Adolesc Health. 2010;47:346–51.
74. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53:32–6.
75. Gilbert-Diamond D, Cottingham KL, Gruber JF, et al. Rice consumption contributes to arsenic exposure in US women. Proc Natl Acad Sci U S A. 2011;108:20656–60.
76. Jackson BP, Taylor VF, Karagas MR, Punshon T, Cottingham KL. Arsenic, organic foods, and brown rice syrup. Environ Health Perspect. 2012;120:623–6.
77. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331–40.
78. Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis. 2010;17:254–64.
79. Critical Aspects of EPA's IRIS Assessment of Inorganic Arsenic: Interim Report: The National Academies Press; 2014.